Bradford Woodworth
Otolaryngology · Birmingham, ALNPI 1720197510
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $18,085 of the $27,370 with a category attached, or 66.1%. 21 manufacturers reported payments, led by Cook Biotech Incorporated at 47.4% of the total. Reporting peaked in 2022 at $9,576 and has fallen 90.7% since, to $894 in 2025. Among otolaryngology clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 93 payments — averaging $294.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cook Biotech Incorporated$13K
- Smith+Nephew$3K
- Cook Incorporated$2K
- Medtronic$2K
- Baxter Healthcare$2K
- Aerin Medical Inc.$1K
- plus $5K from 15 others
Across 25 payments — averaging $11,814 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cook Research Incorporated$184K
- Optinose US, Inc.$111K
What the payments were for
- Consulting fees$18,08566%
- Speaking & faculty fees$2,3008%
- Food & beverage$6,98526%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cook Biotech Incorporated | 2 | $12,985 |
| Smith+Nephew | 5 | $3,018 |
| Cook Incorporated | 2 | $2,300 |
| Medtronic(2 entities) | 17 | $1,758 |
| Baxter Healthcare | 2 | $1,622 |
| Aerin Medical Inc. | 7 | $1,157 |
| Acclarent, Inc | 7 | $810 |
| Regeneron Healthcare Solutions, Inc. | 13 | $717 |
| Intersect ENT, Inc. | 7 | $500 |
| Integra Lifesciences Corporation | 3 | $457 |
| Optinose US, Inc. | 5 | $376 |
| Neurent Medical Limited | 3 | $365 |
| Aroa Biosurgery Incorporated | 3 | $285 |
| Cook Medical LLC | 4 | $198 |
| Sanofi | 4 | $181 |
| Inspire Medical Systems, Inc. | 1 | $177 |
| Johnson & Johnson | 3 | $135 |
| GSK | 1 | $120 |
| Stryker | 2 | $83 |
| AstraZeneca | 1 | $80 |
| RTI Surgical, Inc | 1 | $46 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Coblation - Sinus Wands$2,500
- Entact$2,500
- Cook Medical Biodesign$2,300
- FLOSEAL$1,622
- TruDi Nav Cable$732
- VIVAER STYLUS$526
- RHINAER STYLUS$526
- PROCISE Sinus$500
- PROPEL$406
- DUPIXENT$372
- Acclarent Aera$310
- Inspira Air$310
- RELIEVA SPINPLUS NAV$310
- TruDi Probe$310
- STEALTHSTATION S8 PLATFORM$274
- Xhance$256
- NEUROMARK Device$218
- NEUROMARK Radiofrequency Console$218
- Inspire Upper Airway Stimulation System$177
- STRAIGHTSHOT$175
How this compares
$27,370 in reported general payments places this provider in the 95th percentile of 155 otolaryngology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 140 | $499,050 |
| Dupixent SyringeDupilumab | 11 | $39,959 |
| XhanceFluticasone Propionate | 46 | $33,688 |
| Ipratropium Bromide | 43 | $1,449 |
| Acetazolamide ErAcetazolamide | 27 | $1,363 |
| Acetazolamide | 16 | $955 |
| Azelastine Hcl | 11 | $548 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 31 | $532 |
| Azithromycin | 18 | $416 |
| Montelukast Sodium | 22 | $403 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 37 | $379 |
| Ciprofloxacin Hcl | 30 | $361 |
| Fluticasone Propionate | 13 | $310 |
| Doxycycline Hyclate | 12 | $210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Optinose US, Inc.Xhance | $376 | $33,68846 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 155 otolaryngology providers in Alabama.
Other otolaryngology in Birmingham
- Michael SillersBirmingham$53K
- Justin TurnerBirmingham$34K
- Patrick OwensBirmingham$26K
- Kirk WithrowBirmingham$22K
- Do-Yeon ChoBirmingham$19K
- Andrew FusonBirmingham$18K
- Benjamin GreeneBirmingham$15K
- William BarberBirmingham$13K
- Dennis PappasBirmingham$13K
- Ryan MarshallBirmingham$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.